Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy

• Published in: PloS one Vol. 13; no. 9; p. e0203216
• Main Authors: Pal, Abhijit Ricky, Mercer, Jean, Jones, Simon A, Bruce, Iain A, Bigger, Brian W
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 18-09-2018; Public Library of Science (PLoS)
• Subjects: Accumulation; Airway management; Analysis; Biochemical analysis; Biology; Biology and Life Sciences; Care and treatment; Collagen; Collagen (type IV); Cytokines; Disease; Enzyme therapy; Enzymes; Extracellular matrix; Genetic aspects; Genetic disorders; Genotype & phenotype; Glycosaminoglycans; Health aspects; Heparan sulfate; Hospitals; Hydrolase; Immunohistochemistry; Inflammation; Interleukin 6; Laminin; Lysosomal storage diseases; Medicine; Medicine and Health Sciences; Metabolic disorders; Metabolism; Mucopolysaccharidoses; Mucopolysaccharidosis; Otolaryngology; Patients; Phenotypes; Respiratory tract diseases; Sleep; Stem cells; Substrates; Therapy; Tumor necrosis factor-α; United Kingdom > UK; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0203216

Mucopolysaccharide diseases are a group of lysosomal storage disorders caused by deficiencies of hydrolase enzymes, leading to pathological glycosaminoglycan accumulation. A number of mucopolysaccharidosis (MPS) types are characterised by severe airway disease, the aetiology of which is poorly understood. There is ongoing evidence of significant clinical disease in the long-term despite disease modifying therapeutic strategies, including enzyme-replacement therapy (ERT). To provide a better understanding of this aspect of disease, we have characterised extracellular matrix (ECM) and inflammatory alterations in adenotonsillar tissue samples from 8 MPS patients.
Adenotonsillar samples from MPS I, IVA and VI ERT treated patients and from a single enzyme naïve MPS IIIA individual were compared to non-affected control samples using quantitative immunohistochemistry, qPCR and biochemical analysis.
Significantly increased lysosomal compartment size and total sulphated glycosaminoglycan (p = 0.0007, 0.02) were identified in patient samples despite ERT. Heparan sulphate glycosaminoglycan was significantly elevated in MPS I and IIIA (p = 0.002), confirming incomplete reversal of disease. Collagen IV and laminin α-5 (p = 0.002, 0.0004) staining demonstrated increased ECM deposition within the reticular and capillary network of MPS samples. No significant change in the expression of the pro-inflammatory cytokines IL-1α, IL-6 or TNF-α was seen compared to control.
This study suggests a role for ECM remodelling contributing to the obstructive phenotype of airway disease in MPS. Current therapeutic strategies with ERT fail to normalise these pathological alterations within adenotonsillar samples. Our findings lend novel insight into the pathological cascade of events, with primarily structural rather than inflammatory changes contributing to the continuing phenotype seen in patients despite current therapeutic regimes.